The Proteasome Inhibitor, MG132, Attenuates Diabetic Nephropathy by Inhibiting SnoN Degradation In Vivo and In Vitro
Joint Authors
Yang, Chen
Gao, Chenlin
Yan, Pijun
Peng, Juan
Gou, Fang
Nan, Qinling
Xu, Yong
Chen, Guo
Huang, Wei
Feng, Hong
Zhang, Zhihong
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-06-09
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Transforming growth factor-β (TGF-β) has been shown to be involved in diabetic nephropathy (DN).
The SnoN protein can regulate TGF-β signaling through interaction with Smad proteins.
Recent studies have shown that SnoN is mainly degraded by the ubiquitin-proteasome pathway.
However, the role of SnoN in the regulation of TGF-β/Smad signaling in DN is still unclear.
In this study, diabetic rats were randomly divided into a diabetic control group (DC group) and a proteasome inhibitor (MG132) diabetes therapy group (DT group).
Kidney damage parameters and the expression of SnoN, Smurf2, and TGF-β were observed.
Simultaneously, we cultured rat glomerular mesangial cells (GMCs) stimulated with high glucose, and SnoN and Arkadia expression were measured.
Results demonstrated that 24-hour urine protein, ACR, BUN, and the expression of Smurf2 and TGF-β were significantly increased (P<0.05), whereas SnoN was significantly decreased in the DC group (P<0.05).
However, these changes diminished after treatment with MG132.
SnoN expression in GMCs decreased significantly (P<0.05), but Arkadia expression gradually increased due to high glucose stimulation (P<0.05), which could be almost completely reversed by MG132 (P<0.05).
The present results support the hypothesis that MG132 may alleviate kidney damage by inhibiting SnoN degradation and TGF-β activation, suggesting that the ubiquitin-proteasome pathway may become a new therapeutic target for DN.
American Psychological Association (APA)
Huang, Wei& Yang, Chen& Nan, Qinling& Gao, Chenlin& Feng, Hong& Gou, Fang…[et al.]. 2014. The Proteasome Inhibitor, MG132, Attenuates Diabetic Nephropathy by Inhibiting SnoN Degradation In Vivo and In Vitro. BioMed Research International،Vol. 2014, no. 2014, pp.1-11.
https://search.emarefa.net/detail/BIM-490384
Modern Language Association (MLA)
Huang, Wei…[et al.]. The Proteasome Inhibitor, MG132, Attenuates Diabetic Nephropathy by Inhibiting SnoN Degradation In Vivo and In Vitro. BioMed Research International No. 2014 (2014), pp.1-11.
https://search.emarefa.net/detail/BIM-490384
American Medical Association (AMA)
Huang, Wei& Yang, Chen& Nan, Qinling& Gao, Chenlin& Feng, Hong& Gou, Fang…[et al.]. The Proteasome Inhibitor, MG132, Attenuates Diabetic Nephropathy by Inhibiting SnoN Degradation In Vivo and In Vitro. BioMed Research International. 2014. Vol. 2014, no. 2014, pp.1-11.
https://search.emarefa.net/detail/BIM-490384
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-490384